Astellas Announces Preliminary Phase 1/2 Safety, Tolerability and Efficacy Data for ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukaemia
Chertsey, England (ots/PRNewswire) - - Results from Phase 1/2 trial investigating drug candidate for rare, aggressive blood cancer announced at European Hematology Association Congress; Phase 3 trial planned for late 2015 Astellas Pharma Europe today announced that preliminary data from a Phase 1/2 trial[a] on the ...
plus